The renin-angiotensin system (RAS) plays a vital role in developing thoracic aortic aneurysms (TAAs) and AAAs; thus, pharmaceutical ACE inhibition reduces the risk of aneurysm formation. Here, ACE is linked to achalasia-alacrima syndrome.